Pharma: Clinic Roundup
Wednesday, February 29, 2012
Forest Laboratories Inc., of New York, reported top-line results from two Phase III trials of cariprazine (RGH-188) in acute exacerbation of schizophrenia, showing that patients treated with the dopamine D3-preferring D3/D2 receptor partial agonist experienced significant symptom improvement compared to the placebo group, as measured by the Positive And Negative Syndrome Scale, the primary endpoint in both studies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.